Corona Remedies, made a stellar debut on Dalal Street on Monday, entering with a 38.42% premium over the IPO price of Rs 1,062.The share will be available for trading on NSE and BSE.On the National Stock Exchange, Corona Remedies was trading at 1470, and at 1473, up 1.45% on the BSE, around 11:11 AM.
Corona Remedies IPO
The Rs 655-crore initial public offering, fully structured as an offer for sale, saw an overwhelming response from investors. The issue was oversubscribed 144.5 times overall, driven by institutional investors. Qualified institutional buyers subscribed nearly 294 times, non-institutional investors over 220 times, and retail investors also participated strongly, taking up their allocation more than 30 times, according to ET. This demand highlighted strong confidence in the company’s business strategy, product range, and earnings potential.Corona Remedies did not raise fresh capital through the IPO and all proceeds went to selling shareholders. The company entered the public markets with a healthy balance sheet and a record of consistent profitability. Based on the IPO price, the company’s market valuation stands at approximately Rs 6,495 crore, with a post-issue price-to-earnings multiple of around 35 times, calculated using annualized FY26 earnings. While the valuation is on the higher side, investors appear willing to pay a premium for steady growth, high margins, and leadership in select therapy areas.
financial scoreboard
The company has shown strong growth financially. Revenue for FY25 rose 18% year-on-year to Rs 1,202 crore, while profit after tax jumped 65% to Rs 149 crore. For the quarter that ended in June 2025, PAT stood at Rs 46 crore, signaling sustained momentum into FY26. Return ratios remain robust, with ROE at 27.5% and ROCE over 41%, aided by disciplined capital management and a low debt-to-equity ratio of 0.1.Anchor investors had already committed close to Rs 195 crore before the IPO, lending credibility and stability to the offering. The participation of long-only domestic and global funds in the anchor book helped set the tone for strong institutional demand during the public sale.
About Corona Remedies
Corona Remedies focuses on women’s healthcare, cardiology, pain management, urology, and other chronic therapies. The firm’s distribution network spans 22 states and has over 2,600 medical representatives.
